FILTER

LATEST INTERVIEWS

Dr. Jim Li

CEO, SUNDIA
Sundia is a CRO based in China and speaks to GBR of the evolution of the drug discovery process in China.

Suresh Vadnagra

EXECUTIVE GENERAL MANAGER OPERATIONS AMERICAS, MMG & PRESIDENT, MINERA LAS BAMBAS
MMG speaks to GBR about the first year of production at the vast Las Bambas copper mine.

Maurice Mason

VP CORPORATE DEVELOPMENT & INVESTOR RELATIONS, CALEDONIA MINING CORPORATION
Caledonia Mining Corporation speaks about its gold mining activities in Zimbabwe.

Erdem Tüzünalp

REGIONAL GENERAL MANAGER, TURKEY & MENA, EPIROC
"Turkey is still relatively new to mining but there are a lot of reserves and after the privatization drive, the industry grew rapidly. However, we still do not have a high enough level of exploration and there are social and environmental problems, which means it is difficult to get permits."

Jeffrey A Quartermaine

CEO AND Managing Director, PERSEUS MINING
Perseus became a multi-mine, multi-jurisdiction gold producer in January 2018 and persists in its quest to operate three mines in West Africa by 2020.

Víctor Gobitz

CEO, BUENAVENTURA
“El Brocal's Marcapunta mine could reach 20,000 tonnes per day"

Brendan Borg

MANAGING DIRECTOR, CELSIUS RESOURCES
Celsius Resources speaks to GBR about the development of its cobalt project in Namibia.

Prof. Dr. Güven Önal

PRESIDENT, TURKISH MINING DEVELOPMENT FOUNDATION
The Turkish Mining Development Foundation speaks with GBR about the current state of the Turkish mining industry.

Dr. Xu Jia

CONSULTING LEADER, PWC CHINA HEALTHCARE AND PHARMACEUTICALS
PwC in China is benefitting from the rise of the biopharma and a flurry of IPO and acquisition activities in the pharma industry more generally.

Amaury Lescaux

MANAGING DIRECTOR, SMT
SMT has expanded its Volvo dealership within and beyond Africa.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.

PARTNER EVENTS